Novel Therapeutics for Translation Control in Breast Cancer

乳腺癌翻译控制的新疗法

基本信息

  • 批准号:
    8385792
  • 负责人:
  • 金额:
    $ 21.28万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-08-10 至 2014-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): There is a fundamental gap in understanding how eukaryotic elongation factor 2 kinase (eEF-2K) enhances breast tumor cell survival and proliferation. The long-term goal is to understand how to manipulate eEF-2K through 5-HT1B/1D receptor signaling using triptan derivatives with the therapeutic purpose of treating breast cancer. The objective here, which is the next step in pursuit of that goal, is to establish the mechanism of action of 5-nonylytryptamine (5-NT), a triptan, in vitro, and to validate that it functions via the same mechanism in vivo. The central hypothesis is that 5-NT exhibits potent anti- breast tumor activity by signaling through the 5-HT1B/1D receptors, which are over-expressed in breast cancer cells. This leads to the down-regulation of eEF-2K, which in turn negatively modulates mTOR. We also hypothesize that neutrally charged nanoliposomes carrying 5-NT effectively curb the growth of primary and metastatic tumors in vivo by exerting the same negative effects on critical pro-tumorigenic signaling pathways as those observed in vitro. The hypothesis was formulated based on our preliminary data, which indicate that in breast cancer cells, the siRNA-mediated down-regulation of eEF-2K induces apoptosis, and inhibits cell proliferation and migration. Additionally, critical signaling proteins including mTOR cMyc, IGF-1R and Src are down-regulated. Significantly, we found that 5-NT down-regulates eEF-2K and exhibits similar effects to targeting eEF-2K by siRNA in both in vitro and in vivo breast cancer models. The rationale for the proposed research is that once the mechanism by which 5-NT hinders breast cancer cell proliferation has been elucidated, strategies for the molecular targeting of 5- HT1B/1D will be effectively formulated. Guided by strong preliminary data, our hypothesis will be tested by pursuing two specific aims: 1) Delineate the mechanism of action of 5-NT in breast cancer cells; and 2) Investigate the pharmacokinetics and pharmacodynamics properties as a guide to optimizing the in vivo antitumor activity of nanoliposomes carrying 5-NT. Under the first aim, 5-HT1B/1D levels will be modulated to ascertain their role in 5-NT antitumor activity and eEF-2K stability. Modulation of protein translation will be analyzed as well as levels of potential biomarkers such as phospho-mTOR. Under the second aim, a novel yet proven drug delivery technique utilizing neutral nanoliposomes, will be used for 5-NT delivery, followed by analysis of eEF-2K, mTOR and pro-tumorigenic signaling pathways in metastatic human breast tumors in an in vivo orthotopic xenograft breast cancer model in nude mice. The proposed research is innovative because it focuses on an entirely novel mechanism of cancer therapy using the triptan 5-NT, which signals the down-regulation of several key pro-tumorigenic kinases including eEF-2K, C-Src, IGF-1R and mTOR. This research is significant because it would allow, for the first time, the development of novel and much needed approaches to target breast cancer. 1 PUBLIC HEALTH RELEVANCE: Our recent work indicates that a triptan drug can promote responses in breast cancer cells that lead to their death. The work in this proposal aims to understand this response and to develop the use of this drug as a breast cancer therapy. The studies proposed will be of high significance and will benefit public health.
描述(由申请人提供):在理解真核延长因子2激酶(EEF-2K)如何促进乳腺肿瘤细胞存活和增殖方面存在着根本的空白。长期目标是了解如何使用Triptan衍生物通过5-HT1B/1D受体信号来操纵EEF-2K,从而达到治疗乳腺癌的目的。这里的目标是建立雷公藤多苷的体外作用机制,并验证其在体内是否通过相同的机制发挥作用。中心假设是,5-NT通过在乳腺癌细胞中过度表达的5-HT1B/1D受体发出信号,从而显示出强大的抗乳腺肿瘤活性。这导致EEF-2K的下调,进而负向调节mTOR。我们还假设,携带5-NT的中性电荷纳米脂质体通过对关键的促肿瘤信号通路产生与体外观察相同的负面影响,有效地抑制体内原发和转移肿瘤的生长。这一假说是基于我们的初步数据提出的,这些数据表明,在乳腺癌细胞中,siRNA介导的EEF-2K下调诱导了细胞凋亡,并抑制了细胞的增殖和迁移。此外,关键信号蛋白包括mTOR cMyc、IGF-1R和Src下调。值得注意的是,我们发现,在体外和体内乳腺癌模型中,5-NT下调EEF-2K,并显示出与siRNA靶向EEF-2K相似的效果。这项研究的理论基础是,一旦阐明了5-NT阻碍乳腺癌细胞增殖的机制,就可以有效地制定5-HT1B/1D的分子靶向策略。在强大的初步数据的指导下,我们的假设将通过追求两个特定的目标来验证:1)描述5-NT在乳腺癌细胞中的作用机制;2)研究5-NT的药代动力学和药效学性质,以指导优化携带5-NT的纳米脂质体的体内抗肿瘤活性。在第一个目标下,5-HT1B/1D水平将被调节,以确定它们在5-NT抗肿瘤活性和EEF-2K稳定性中的作用。将分析蛋白质翻译的调节以及潜在生物标记物的水平,如磷酸化mTOR。在第二个目标下,一种利用中性纳米脂质体的新型药物传递技术将用于5-NT的传递,随后将在裸鼠原位移植乳腺癌模型中分析转移性人乳腺肿瘤的EEF-2K、mTOR和促肿瘤信号通路。这项拟议的研究具有创新性,因为它专注于一种全新的使用Triptan 5-NT治疗癌症的机制,该机制发出信号下调几个关键的促肿瘤激酶,包括EEF-2K、C-Src、IGF-1R和mTOR。这项研究意义重大,因为它将首次允许开发新的和迫切需要的方法来靶向乳腺癌。1 公共卫生相关性:我们最近的工作表明,一种曲普坦药物可以促进乳腺癌细胞的反应,导致它们死亡。这项提案中的工作旨在了解这种反应,并开发这种药物作为乳腺癌治疗的使用。建议的研究将具有重要意义,并将有益于公众健康。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kevin N Dalby其他文献

Kevin N Dalby的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kevin N Dalby', 18)}}的其他基金

Dual-Mechanism Allosteric Inhibitors of ERK Signaling
ERK 信号双机制变构抑制剂
  • 批准号:
    10446852
  • 财政年份:
    2022
  • 资助金额:
    $ 21.28万
  • 项目类别:
Dual-Mechanism Allosteric Inhibitors of ERK Signaling
ERK 信号双机制变构抑制剂
  • 批准号:
    10614057
  • 财政年份:
    2022
  • 资助金额:
    $ 21.28万
  • 项目类别:
Regulation of eEF-2K an Energy and Nutrient Sensor
能量和营养传感器 eEF-2K 的调节
  • 批准号:
    10658322
  • 财政年份:
    2017
  • 资助金额:
    $ 21.28万
  • 项目类别:
Mechanism of Activation of eEF-2K, an Energy and Nutrient Sensor
能量和营养传感器 eEF-2K 的激活机制
  • 批准号:
    9289618
  • 财政年份:
    2017
  • 资助金额:
    $ 21.28万
  • 项目类别:
Novel Therapeutics for Translation Control in Breast Cancer
乳腺癌翻译控制的新疗法
  • 批准号:
    8528524
  • 财政年份:
    2012
  • 资助金额:
    $ 21.28万
  • 项目类别:
Mechanism and Specificity of MAP Kinases
MAP 激酶的机制和特异性
  • 批准号:
    6333277
  • 财政年份:
    2001
  • 资助金额:
    $ 21.28万
  • 项目类别:
Mechanism and Specificity of MAP Kinases
MAP 激酶的机制和特异性
  • 批准号:
    6868982
  • 财政年份:
    2001
  • 资助金额:
    $ 21.28万
  • 项目类别:
ERK2: Structure, Function and Inhibition
ERK2:结构、功能和抑制
  • 批准号:
    8130662
  • 财政年份:
    2001
  • 资助金额:
    $ 21.28万
  • 项目类别:
Mechanism and Specificity of MAP Kinases
MAP 激酶的机制和特异性
  • 批准号:
    6636337
  • 财政年份:
    2001
  • 资助金额:
    $ 21.28万
  • 项目类别:
Mechanism and Specificity of MAP Kinases
MAP 激酶的机制和特异性
  • 批准号:
    6727675
  • 财政年份:
    2001
  • 资助金额:
    $ 21.28万
  • 项目类别:

相似国自然基金

Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 批准年份:
    2020
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 批准年份:
    2017
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 批准年份:
    2016
  • 资助金额:
    58.0 万元
  • 项目类别:
    面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 批准年份:
    2014
  • 资助金额:
    73.0 万元
  • 项目类别:
    面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
  • 批准号:
    81301123
  • 批准年份:
    2013
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
  • 批准号:
    81101529
  • 批准年份:
    2011
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
  • 批准号:
    39500043
  • 批准年份:
    1995
  • 资助金额:
    9.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Milk fat globule-EGF factor 8 and hepatocyte apoptosis-induced liver wound healing response
乳脂肪球-EGF因子8与肝细胞凋亡诱导的肝脏创面愈合反应
  • 批准号:
    10585802
  • 财政年份:
    2023
  • 资助金额:
    $ 21.28万
  • 项目类别:
Development of an apoptosis biosensor for monitoring of breast cancer
开发用于监测乳腺癌的细胞凋亡生物传感器
  • 批准号:
    10719415
  • 财政年份:
    2023
  • 资助金额:
    $ 21.28万
  • 项目类别:
Interrogating the Fgl2-FcγRIIB axis on CD8+ T cells: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
询问 CD8 T 细胞上的 Fgl2-FcγRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
  • 批准号:
    10605856
  • 财政年份:
    2023
  • 资助金额:
    $ 21.28万
  • 项目类别:
Novel targeted therapy for FGFR inhibitor-resistant urothelial cancer and apoptosis based therapy for urothelial cancer
FGFR抑制剂耐药性尿路上皮癌的新型靶向治疗和基于细胞凋亡的尿路上皮癌治疗
  • 批准号:
    23K08773
  • 财政年份:
    2023
  • 资助金额:
    $ 21.28万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Mechanistic analysis of apoptosis induction by HDAC inhibitors in head and neck cancer
HDAC抑制剂诱导头颈癌凋亡的机制分析
  • 批准号:
    23K15866
  • 财政年份:
    2023
  • 资助金额:
    $ 21.28万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Interrogating the Fgl2-FcgRIIB axis: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
探究 Fgl2-FcgRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
  • 批准号:
    10743485
  • 财政年份:
    2023
  • 资助金额:
    $ 21.28万
  • 项目类别:
Investigating the role of apoptosis-resistance and the tumor environment on development and maintenance of sacrococcygeal teratomas
研究细胞凋亡抗性和肿瘤环境对骶尾部畸胎瘤发生和维持的作用
  • 批准号:
    10749797
  • 财政年份:
    2023
  • 资助金额:
    $ 21.28万
  • 项目类别:
The effects of glucose on immune cell apoptosis and mitochondrial membrane potential and the analysis of its mechanism by which glucose might modulate the immune functions.
葡萄糖对免疫细胞凋亡和线粒体膜电位的影响及其调节免疫功能的机制分析。
  • 批准号:
    22K09076
  • 财政年份:
    2022
  • 资助金额:
    $ 21.28万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
XAF1 IN P53 SIGNALING, APOPTOSIS AND TUMOR SUPPRESSION
P53 信号传导、细胞凋亡和肿瘤抑制中的 XAF1
  • 批准号:
    10583516
  • 财政年份:
    2022
  • 资助金额:
    $ 21.28万
  • 项目类别:
Role of Thioredoxin system in regulation of autophagy-apoptosis cross talk in neurons: Uncovering Novel Molecular Interactions.
硫氧还蛋白系统在神经元自噬-凋亡串扰调节中的作用:揭示新的分子相互作用。
  • 批准号:
    RGPIN-2019-05371
  • 财政年份:
    2022
  • 资助金额:
    $ 21.28万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了